Ovarian Cancer Clinical Trials (2026): 585 Recruiting Interventional Studies

Last updated: April 2, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

First-Line Maintenance (After Platinum Response)

PARP inhibitors ± bevacizumab are standard maintenance. Trials test new combinations and non-HRD strategies:

• NCT07472140 - PARP inhibitor ± angiogenesis inhibitor in HRD-positive primary ovarian cancer (Phase 3)
• NCT06953584 - Fluzoparib + Bevacizumab/dietary intervention vs Fluzoparib monotherapy in HRD+/- (Phase 3)
• NCT06580314 - Olaparib for 1 vs 2 years ± Bevacizumab (Phase 3)
• NCT06819007 - DESTINY-Ovarian01: T-DXd + Bevacizumab vs Bevacizumab maintenance in HER2-expressing (Phase 3)
• NCT07318558 - Sacituzumab Tirumotecan (MK-2870) in non-HRD positive advanced ovarian cancer (Phase 3)

Platinum-Sensitive Recurrence

• NCT07225270 - Rina-S (ADC) + SOC vs SOC for maintenance after 2L platinum-based chemo (Phase 3)
• NCT06824467 - Sacituzumab Tirumotecan (MK-2870) maintenance vs SOC in platinum-sensitive recurrence (Phase 3)
• NCT07213804 - Sofetabart Mipitecan (ADC) in platinum-sensitive ovarian cancer (Phase 3, Part B)
• NCT05009082 - Niraparib vs Niraparib + Bevacizumab after platinum/taxane chemo (Phase 3)
• NCT05255471 - MITO 35B: Olaparib beyond progression vs platinum chemo after secondary cytoreduction (Phase 3)

Platinum-Resistant / Refractory

Major unmet need. ADCs and novel agents are transforming this space:

• ADCs:
  • NCT07218809 - AZD5335 vs Mirvetuximab (FRα-high) and AZD5335 vs Chemo (FRα-low) in platinum-resistant (Phase 3)
  • NCT06161025 - Raludotatug Deruxtecan (R-DXd) in platinum-resistant high-grade ovarian cancer (Phase 3)
  • NCT06834672 - IBI354 vs Chemo in platinum-resistant ovarian cancer (Phase 3)
  • NCT06394492 - SHR-A1921 in platinum-resistant recurrent EOC (Phase 3)
  • NCT06828354 - SHR-A1811 (T-DXd analog) in ovarian cancer (Phase 3)
  • NCT06994195 - BL-B01D1 (EGFR×HER3 bispecific ADC) vs Chemo in platinum-resistant (Phase 3)
• Novel agents:
  • NCT07214779 - INCB123667 vs Chemo in platinum-resistant with Cyclin E1 overexpression (Phase 3)
  • NCT05281471 - OnPrime: Olvi-Vec (oncolytic virus) + platinum-doublet + bevacizumab vs Chemo + Bevacizumab (Phase 3)
  • NCT04921527 - Chiauranib + weekly paclitaxel in platinum-resistant recurrence (Phase 3)

Surgery & Perioperative

• NCT04575935 - LANCE: Minimally invasive surgery after NACT for stage IIIC-IV (Phase 3)
• NCT03772028 - Primary cytoreductive surgery ± HIPEC (Phase 3)
• NCT05827523 - FOCUS: Interval cytoreductive surgery ± HIPEC (Phase 3)
• NCT06915025 - IMNN-001 + standard NACT and adjuvant chemo in newly diagnosed advanced EOC (Phase 3)

Specific Histologies

• Low-grade serous:
  • NCT06072781 - Avutometinib (MEKi) + Defactinib (FAKi) in recurrent LGSOC (Phase 3)
  • NCT05601700 - LEPRE: Letrozole for ER/PR-positive LGSOC (Phase 3)
• Early-stage:
  • NCT04063527 - Stage I ovarian cancer after surgery (Phase 3)

Novel Approaches

• Next-gen ADCs: Raludotatug deruxtecan (CLN-619, FRα-targeted), sofetabart mipitecan, IBI354, SHR-A1921 — multiple new ADCs racing to improve on mirvetuximab
• Non-HRD maintenance: Sacituzumab tirumotecan, T-DXd — extending maintenance beyond BRCA/HRD patients
• Cyclin E1 targeting: INCB123667 for platinum-resistant ovarian cancer with CCNE1 amplification — biomarker-selected approach
• Oncolytic virus: Olvi-Vec combined with platinum chemotherapy for platinum-resistant disease
• Personalized vaccines: NCT06341907 - MRD + personalized vaccine for recurrence prevention after EOC surgery

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Frequently Asked Questions